Reading view
Explaining Decisions in ML Models: a Parameterized Complexity Analysis (Part I)
Digital Transformation Chatbot (DTchatbot): Integrating Large Language Model-based Chatbot in Acquiring Digital Transformation Needs
Generative Artificial Intelligence in Bioinformatics: A Systematic Review of Models, Applications, and Methodological Advances
REFA: Reference Free Alignment for multi-preference optimization
Drugmakers share data to feed voracious foundation models
Nature Biotechnology, Published online: 06 November 2025; doi:10.1038/s41587-025-02901-8
Big pharma shares its machine learning models with biotechs, but awaits definitive data on success of artificial intelligence-generated drugs.Site-specific DNA insertion into the human genome with engineered recombinases
Nature Biotechnology, Published online: 06 November 2025; doi:10.1038/s41587-025-02895-3
Engineered DNA recombinases efficiently and specifically insert genetic cargos without the use of landing pads.STAT+: What’s FDA plotting for therapy chatbot regulation?
You’re reading the web edition of STAT’s Health Tech newsletter, our guide to how technology is transforming the life sciences. Sign up to get it delivered in your inbox every Tuesday and Thursday.
What to know about the FDA’s therapy bots meeting
The Food and Drug Administration is considering whether and how to regulate therapy chatbots that are based on large language models. Today, the agency’s Digital Health Advisory Committee is meeting to consider the topic. In a new story, I explain what’s going on, including some fresh insider intel.
The FDA wants to provide more clarity to developers of generative AI medical devices about what needs regulatory green light and how to get it. The agency is also also worried about LLM-based therapy bots that can provide unpredictable outputs. Regulators are aware about the growing concerns around general purpose bots like ChatGPT, which have been linked to delusions and allegedly to suicides.
Continue to STAT+ to read the full story…


© Sarah Silbiger/Getty Images
Improving dataset transparency in dermatologic Artificial Intelligence using a dataset nutrition label
npj Digital Medicine, Published online: 05 November 2025; doi:10.1038/s41746-025-02125-9
Biased and poorly documented dermatology datasets pose risks to the development of safe and generalizable artificial intelligence (AI) tools. We created a Dataset Nutrition Label (DNL) for multiple dermatology datasets to support transparent and responsible data use. The DNL offers a structured, digestible summary of key attributes, including metadata, limitations, and risks, enabling data users to better assess suitability and proactively address potential sources of bias in datasets.Evaluating clinical AI summaries with large language models as judges
npj Digital Medicine, Published online: 05 November 2025; doi:10.1038/s41746-025-02005-2
Evaluating clinical AI summaries with large language models as judgesLiquid biopsy in gastrointestinal oncology: clinical applications and translational integration of ctDNA, CTCs, and sEVs
Oncol Rev. 2025 Oct 20;19:1702932. doi: 10.3389/or.2025.1702932. eCollection 2025.
ABSTRACT
BACKGROUND AND AIMS: Liquid biopsy offers a minimally invasive tool to detect actionable mutations, monitor minimal residual disease (MRD), and guide therapy in gastrointestinal (GI) cancers. We critically review the clinical utility of circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), and small extracellular vesicles (sEVs) across GI malignancies and propose a framework for their integration into clinical practice.
METHODS: We synthesized evidence from over 200 studies, including prospective trials and translational research, to assess diagnostic accuracy, prognostic value, and clinical actionability of each biomarker type in esophageal, gastric, colorectal, pancreatic, hepatocellular, and biliary cancers.
RESULTS: ctDNA has shown strong potential for MRD detection and treatment monitoring, particularly in colorectal and pancreatic cancer. CTCs offer insights into metastatic risk and therapeutic resistance, while sEVs provide molecular cargo relevant to immunomodulation and disease progression. Emerging microfluidics and AI-driven multi-omics approaches may overcome current limitations.
CONCLUSION: The integration of liquid biopsy technologies into GI oncology holds promise for early detection and precision therapy. We propose a five-phase clinical roadmap and outine the key research gaps that need to be addressed before widespread implementation in routine care.
PMID:41190015 | PMC:PMC12580207 | DOI:10.3389/or.2025.1702932
Combining International Standards to Develop Clinical Decision Support for Parent Smoking Cessation in Pediatrics
A multimodal whole-slide foundation model for pathology
Nature Medicine, Published online: 05 November 2025; doi:10.1038/s41591-025-03982-3
Pretrained using 335,645 whole-slide images, a foundation model is developed to provide representations for slide- and patient-level tasks. It is capable of performing clinical tasks and generating reports even in data-scarce scenarios, such as rare cancer diagnosis and survival prediction, without requiring further fine-tuning.Fair human-centric image dataset for ethical AI benchmarking
Nature, Published online: 05 November 2025; doi:10.1038/s41586-025-09716-2
The Fair Human-Centric Image Benchmark (FHIBE, pronounced ‘Feebee’)—an image dataset that implements best practices for consent, privacy, compensation, safety, diversity and utility—can be used responsibly as a fairness evaluation dataset for many human-centric computer vision applications.